Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.53 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2134985 | 1.00 | NPC1 (0.54) | NPC1UCHL1HRH2HRH1LMNA | |
| SCHEMBL2136506 | 1.00 | NPC1 (0.54) | NPC1UCHL1HRH2HRH1LMNA | |
| SCHEMBL14037470 | 0.96 | NPC1 (0.58) | NPC1UCHL1HRH2HRH1LMNA | |
| SCHEMBL25353468 | 0.89 | LMNA (0.56) | NPC1UCHL1HRH2HRH1LMNA | |
| SCHEMBL8221674 | 0.89 | NPC1 (0.55) | NPC1UCHL1HRH2HRH1LMNA | |
| SCHEMBL2136988 | 0.88 | NPC1 (0.52) | NPC1UCHL1HRH2HRH1LMNA | |
| SCHEMBL2132048 | 0.88 | NPC1 (0.52) | NPC1UCHL1HRH2HRH1LMNA | |
| SCHEMBL5206537 | 0.88 | NPC1 (0.54) | NPC1UCHL1HRH2HRH1LMNA | |
| SCHEMBL1251121 | 0.87 | NPC1 (0.53) | NPC1UCHL1HRH2HRH1LMNA | |
| SCHEMBL2136252 | 0.87 | NPC1 (0.53) | NPC1UCHL1HRH2HRH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115557933-B | Bruton tyrosine kinase and mutant degradation agent, composition and application thereof | 杭州和正医药有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023274390-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2023-01-05 | — | — | WO | disclosed |
| CN-115557933-A | Bruton tyrosine kinase and mutant degradation agent, composition and application thereof | 杭州和正医药有限公司 | 2023-01-03 | — | — | CN | disclosed |
| US-9463187-B2 | Methylphenidate derivatives and uses of them | AMPIO PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20120101129-A1 | Methylphenidate Derivatives and Uses of Them | AMPIO PHARMACEUTICALS, INC. | 2012-04-26 | — | — | US | disclosed |
| US-8076485-B2 | Methylphenidate derivatives and uses of them | INSTITUTE FOR MOLECULAR MEDICINE, INC. (US) | 2011-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101129-A1 | Methylphenidate Derivatives and Uses of Them | SLC6A3, COMT, UGT1A1 | NPC1 390/4885UCHL1 1634/4885HRH2 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.